Cargando…
MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer
SIMPLE SUMMARY: MM-129 (1,2,4-triazine derivative) is a novel promising drug candidate against colon cancer. It has the ability to inhibit intracellular pathways promoting tumorigenesis with a simultaneous reduction of PD-L1 expression, a key element of the cancer immune escape axis. MM-129 may also...
Autores principales: | Hermanowicz, Justyna Magdalena, Pawlak, Krystyna, Sieklucka, Beata, Czarnomysy, Robert, Kwiatkowska, Iwona, Kazberuk, Adam, Surazynski, Arkadiusz, Mojzych, Mariusz, Pawlak, Dariusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268553/ https://www.ncbi.nlm.nih.gov/pubmed/34206937 http://dx.doi.org/10.3390/cancers13133203 |
Ejemplares similares
-
Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer
por: Hermanowicz, Justyna Magdalena, et al.
Publicado: (2021) -
Exploration of novel heterofused 1,2,4-triazine derivative in colorectal cancer
por: Hermanowicz, Justyna Magdalena, et al.
Publicado: (2021) -
The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer
por: Rozkiewicz, Dariusz, et al.
Publicado: (2020) -
Simultaneous use of erythropoietin and LFM‐A13 as a new therapeutic approach for colorectal cancer
por: Tankiewicz‐Kwedlo, Anna, et al.
Publicado: (2018) -
Evaluation of Plasma Concentrations of Galectins-1, 2 and 12 in Psoriasis and Their Clinical Implications
por: Nowowiejska, Julia, et al.
Publicado: (2023)